- Home
- WDFC vs NAMS Comparison
WDFC vs NAMS Comparison
Compare WDFC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDFC
- NAMS
- Stock Information
- Founded
- WDFC 1953
- NAMS 2019
- Country
- WDFC United States
- NAMS Netherlands
- Employees
- WDFC N/A
- NAMS N/A
- Industry
- WDFC Major Chemicals
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- WDFC Industrials
- NAMS Health Care
- Exchange
- WDFC Nasdaq
- NAMS Nasdaq
- Market Cap
- WDFC 3.0B
- NAMS 3.1B
- IPO Year
- WDFC N/A
- NAMS N/A
- Fundamental
- Price
- WDFC $191.59
- NAMS $32.42
- Analyst Decision
- WDFC Strong Buy
- NAMS Strong Buy
- Analyst Count
- WDFC 3
- NAMS 9
- Target Price
- WDFC $300.67
- NAMS $41.89
- AVG Volume (30 Days)
- WDFC 157.7K
- NAMS 974.1K
- Earning Date
- WDFC 10-22-2025
- NAMS 11-05-2025
- Dividend Yield
- WDFC 1.95%
- NAMS N/A
- EPS Growth
- WDFC 24.95
- NAMS N/A
- EPS
- WDFC 6.36
- NAMS N/A
- Revenue
- WDFC $612,505,000.00
- NAMS $64,006,000.00
- Revenue This Year
- WDFC $6.13
- NAMS N/A
- Revenue Next Year
- WDFC $5.76
- NAMS $1.67
- P/E Ratio
- WDFC $30.25
- NAMS N/A
- Revenue Growth
- WDFC 6.52
- NAMS 762.15
- 52 Week Low
- WDFC $190.67
- NAMS $14.06
- 52 Week High
- WDFC $292.36
- NAMS $34.62
- Technical
- Relative Strength Index (RSI)
- WDFC 29.91
- NAMS 71.55
- Support Level
- WDFC $190.67
- NAMS $27.15
- Resistance Level
- WDFC $194.99
- NAMS $33.27
- Average True Range (ATR)
- WDFC 3.94
- NAMS 1.58
- MACD
- WDFC -0.53
- NAMS 0.48
- Stochastic Oscillator
- WDFC 5.13
- NAMS 76.97
About WDFC WD-40 Company
WD-40 Co manufactures and sells lubricants and cleaning products. The firm's product categories include maintenance and cleaning products. Maintenance products include the WD-40 signature brand aerosol spray lubricant as well as degreasers, rust removers, and bicycle maintenance products. Cleaning products include toilet cleaners, carpet stain removers and deodorizers, and heavy-duty hand soaps used to clean grease. The company organizes itself into three segments based on geography: Americas, Europe/Middle East/Africa, and Asia-Pacific. The majority of the company's revenue comes from the Americas segment, which includes the United States, Canada, and Latin America.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.